Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ground glass opacity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Ground glass opacity. Displaying page 1 of 1.
    EudraCT Number: 2014-004782-24 Sponsor Protocol Number: PRM-151-202 Start Date*: 2016-03-01
    Sponsor Name:Promedior, Inc.
    Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005881-17 Sponsor Protocol Number: RIN-PF-303 Start Date*: 2022-08-18
    Sponsor Name:UNITED THERAPEUTICS CORPORATION
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002632-24 Sponsor Protocol Number: P160915 Start Date*: 2018-11-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial
    Medical condition: severe acute exacerbation of idiopathic pulmonary fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002119-23 Sponsor Protocol Number: IEO1253 Start Date*: 2020-11-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: COVitaminD Trial: prevention of complications from COVID-19 in cancer patients under active treatment
    Medical condition: Oncological patients in active oncological treatment diagnosed with Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10010029 Colorectal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004755-17 Sponsor Protocol Number: MYST-FACT Start Date*: 2024-10-01
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: PHASE I/II CLINICAL TRIAL OF ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STROMAL CELL THERAPY FOR THE PREVENTION AND TREATMENT OF PULMONARY FIBROSIS SECONDARY TO POST-INFECTIVE ARDS OR ALLOIMMUNE RE...
    Medical condition: PULMONARY FIBROSIS SECONDARY TO ARDS OR ALLOIMMUNE REACTION AFTER TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10022619 Interstitial pulmonary fibrosis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002857-12 Sponsor Protocol Number: GO40241 Start Date*: 2018-04-26
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY I...
    Medical condition: Early Stage Resectable Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) SI (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002464-75 Sponsor Protocol Number: 534 Start Date*: 2022-12-06
    Sponsor Name:Groupe Hospitalier Paris Saint-Joseph
    Full Title: Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial
    Medical condition: Acute exacerbation of idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 18:28:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA